Format

Send to

Choose Destination
Nephrol Dial Transplant. 2016 Feb;31(2):255-61. doi: 10.1093/ndt/gfv346. Epub 2015 Sep 30.

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Author information

1
Department of Renal Medicine, Hull and East Yorkshire Hospitals NHS Trust, Kingston upon Hull, UK Hull York Medical School, East Yorkshire, UK.
2
Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
3
Department of Renal Medicine, Queen Elizabeth Hospital, Birmingham, UK.
4
Department of Renal Medicine, Leicester General Hospital, Leicester, UK.
5
National Heart & Lung Institute, Imperial College London, London, UK.
6
Sheffield Kidney Institute, Sheffield, UK.

Abstract

BACKGROUND:

Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin-angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD.

METHODS:

The STOP-ACEi trial (trial registration: current controlled trials, ISRCTN62869767) is an investigator-led multicentre open-label, randomized controlled clinical trial of 410 participants with advanced (Stage 4 or 5) progressive CKD receiving ACEi, ARBs or both. Patients will be randomized in a 1:1 ratio to either discontinue ACEi, ARB or combination of both (experimental arm) or continue ACEi, ARB or combination of both (control arm). Patients will be followed up at 3 monthly intervals for 3 years. The primary outcome measure is eGFR at 3 years. Secondary outcome measures include the number of renal events, participant quality of life and physical functioning, hospitalization rates, BP and laboratory measures, including serum cystatin-C. Safety will be assessed to ensure that withdrawal of these treatments does not cause excess harm or increase mortality or cardiovascular events such as heart failure, myocardial infarction or stroke.

RESULTS:

The rationale and trial design are presented here. The results of this trial will show whether discontinuation of ACEi/ARBs can improve or stabilize renal function in patients with advanced progressive CKD. It will show whether this simple intervention can improve laboratory and clinical outcomes, including progression to end-stage renal disease, without causing an increase in cardiovascular events.

KEYWORDS:

angiotensin II receptor blocker (ARB); angiotensin-converting enzyme inhibitor (ACEi); chronic kidney disease; eGFR; randomized controlled trial

PMID:
26429974
PMCID:
PMC4725389
DOI:
10.1093/ndt/gfv346
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center